Sagimet Biosciences Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
24
- Stock Symbol
-
SGMT
- Share Price
-
$10.22
- (As of Friday Closing)
Sagimet Biosciences General Information
Description
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Contact Information
Website
www.sagimet.comCorporate Office
- 950 Tower Lane
- STE 1500
- Foster City, CA 94404
- United States
Corporate Office
- 950 Tower Lane
- STE 1500
- Foster City, CA 94404
- United States
Sagimet Biosciences Stock Performance
As of 13-Nov-2026, Sagimet Biosciences’s stock price is $10.22. Its current market cap is $735M with 71.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.22 | $10.93 | $4.50 - $11.45 | $735M | 71.9M | 1.27M | -$1.17 |
Sagimet Biosciences Financials Summary
As of 30-Sep-2026, Sagimet Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 375,939 | 75,950 | (7,491) | 22,357 |
| Revenue | 0 | 0 | 0 | 2,000 |
| EBITDA | (59,863) | (56,889) | (54,454) | (30,736) |
| Net Income | (53,320) | (51,038) | (45,567) | (27,876) |
| Total Assets | 282,093 | 116,482 | 160,259 | 96,719 |
| Total Debt | 2,015 | 78 | 78 | 65 |
Sagimet Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sagimet Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sagimet Biosciences Comparisons
Industry
Financing
Details
Sagimet Biosciences Competitors (54)
One of Sagimet Biosciences’s 54 competitors is Galectin Therapeutics, a Corporation company based in Norcross, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Enanta Pharmaceuticals | Formerly VC-backed | Watertown, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Black Diamond Therapeutics | Formerly VC-backed | Cambridge, MA |
Sagimet Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sagimet Biosciences Patents
Sagimet Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025155977-A1 | Methods of treating nash | Pending | 21-Jan-2024 | ||
| WO-2025155977-A9 | Methods of treating nash | Pending | 21-Jan-2024 | ||
| JP-2026536209-A | Combination of fasn inhibitors and glp-1 agonists for liver disease | Pending | 10-Oct-2023 | ||
| EP-4791391-A1 | Combinations of fasn inhibitors and glp-1 agonists for liver diseases | Pending | 10-Oct-2023 | ||
| WO-2025080818-A1 | Combinations of fasn inhibitors and glp-1 agonists for liver diseases | Inactive | 10-Oct-2023 | A61K31/4178 |
Sagimet Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sagimet Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.02 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Sagimet Biosciences FAQs
-
When was Sagimet Biosciences founded?
Sagimet Biosciences was founded in 2006.
-
Where is Sagimet Biosciences headquartered?
Sagimet Biosciences is headquartered in Foster City, CA.
-
What is the size of Sagimet Biosciences?
Sagimet Biosciences has 24 total employees.
-
What industry is Sagimet Biosciences in?
Sagimet Biosciences’s primary industry is Drug Discovery.
-
Is Sagimet Biosciences a private or public company?
Sagimet Biosciences is a Public company.
-
What is Sagimet Biosciences’s stock symbol?
The ticker symbol for Sagimet Biosciences is SGMT.
-
What is the current stock price of Sagimet Biosciences?
As of 13-Nov-2026 the stock price of Sagimet Biosciences is $10.22.
-
What is the current market cap of Sagimet Biosciences?
The current market capitalization of Sagimet Biosciences is $735M.
-
Who are Sagimet Biosciences’s competitors?
Galectin Therapeutics, Altimmune, Enanta Pharmaceuticals, Cognition Therapeutics, and Black Diamond Therapeutics are some of the 54 competitors of Sagimet Biosciences.
-
What is Sagimet Biosciences’s annual earnings per share (EPS)?
Sagimet Biosciences’s EPS for 12 months was -$1.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
